...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Trading
1
Sep 19, 2022 03:22PM
1
Sep 20, 2022 02:03PM
3
Sep 20, 2022 03:01PM
3
Sep 20, 2022 05:13PM
4
Sep 20, 2022 06:22PM
4
Sep 21, 2022 12:02PM
2
Sep 21, 2022 01:26PM

So the company acknowledges and defends now ZHCLF as legitimate Zenith stock? 
And is the following bolded section correct?

Sorry if this was clarified here already ... I don't own Zenith stock so I don't follow this forum.

  
This is from Yahoo finance

Description

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in Phase 2b clinical trials for the treatment of metastatic castration resistant prostate cancer and metastatic triple negative breast cancer. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. The company was incorporated in 2013 and is headquartered in Calgary, Canada.

2
Sep 21, 2022 07:27PM
3
Sep 21, 2022 08:34PM
5
Sep 22, 2022 03:16PM
6
Sep 22, 2022 03:27PM
3
Sep 23, 2022 08:35AM
Share
New Message
Please login to post a reply